Technical Analysis for AEZS - AEterna Zentaris Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Calm After Storm | Range Contraction | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Pocket Pivot | Bullish Swing Setup | -3.23% | |
Upper Bollinger Band Walk | Strength | -3.23% | |
Above Upper BB | Strength | -3.23% | |
Upper Bollinger Band Touch | Strength | -3.23% | |
Upper Bollinger Band Walk | Strength | 5.00% | |
Inside Day | Range Contraction | 5.00% |
Alert | Time |
---|---|
Possible Inside Day | about 7 hours ago |
60 Minute Opening Range Breakout | about 9 hours ago |
2x Volume Pace | about 11 hours ago |
1.5x Volume Pace | about 11 hours ago |
3x Volume Pace | about 11 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 03/21/2024
AEterna Zentaris Inc. Description
Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company's product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company's products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Clinical Development Treatment Of Cancer Oncology Lymphoma Prostate Cancer Blastoma In Vitro Peptides Bladder Cancer Glioma Growth Hormone Endometrial Cancer Neuroblastoma Cachexia In Vitro Fertilization Gnrh Antagonists
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.38 |
52 Week Low | 1.3601 |
Average Volume | 17,571 |
200-Day Moving Average | 2.25 |
50-Day Moving Average | 1.91 |
20-Day Moving Average | 1.92 |
10-Day Moving Average | 1.98 |
Average True Range | 0.15 |
RSI (14) | 61.24 |
ADX | 34.03 |
+DI | 32.48 |
-DI | 6.16 |
Chandelier Exit (Long, 3 ATRs) | 1.95 |
Chandelier Exit (Short, 3 ATRs) | 2.12 |
Upper Bollinger Bands | 2.13 |
Lower Bollinger Band | 1.71 |
Percent B (%b) | 0.93 |
BandWidth | 22.18 |
MACD Line | 0.06 |
MACD Signal Line | 0.03 |
MACD Histogram | 0.0278 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.30 | ||||
Resistance 3 (R3) | 2.30 | 2.23 | 2.26 | ||
Resistance 2 (R2) | 2.23 | 2.18 | 2.23 | 2.25 | |
Resistance 1 (R1) | 2.17 | 2.15 | 2.14 | 2.17 | 2.24 |
Pivot Point | 2.10 | 2.10 | 2.09 | 2.10 | 2.10 |
Support 1 (S1) | 2.04 | 2.05 | 2.01 | 2.04 | 1.96 |
Support 2 (S2) | 1.97 | 2.02 | 1.97 | 1.95 | |
Support 3 (S3) | 1.91 | 1.97 | 1.94 | ||
Support 4 (S4) | 1.91 |